A collaborative initiative to explore models, lessons, and frameworks to support the Independent Panel on Evidence for Action Against Antimicrobial Resistance

INAMRSS was founded to advance social science research on infectious diseases, including but not limited to antimicrobial resistance (AMR). In 2026, we are partnering with ESCMID Global (17-21 April i...

YouTube video by Global Strategy Lab

Antimicrobial resistance (AMR) is one of the greatest health challenges of our time, responsible for 1.14 million deaths a year. Failure to keep resistance in check could lead to $1.7 trillion dollars...

Antimicrobial resistance (AMR) poses an important global health challenge, including insufficient investment in research and development. This study q…

Innovations for Gram-Negative Antibiotic Discovery Grand Challenges RFP

In 2021 alone, AMR killed an estimated 1.14 million people annually—and if countries stick to a business-as-usual approach, it could claim 39 million lives between 2025 and 2050. Beyond the human toll...

Significant reductions in methicillin resistance in S aureus, vancomycin-resistant E faecium, and fluoroquinolone resistance across multiple pathogens suggest that control efforts have had an effect on resistance. The rise in extended-spectrum β-lactamases-producing Enterobacterales and recent surge in hospital-associated infections emphasise the need for ongoing surveillance and interventions. Our study highlights how coupling the analysis of phenotypic incidence with resistance proportion can enhance interpretation of antimicrobial resistance data.

Researchers are trying to understand why resistant pathogens are so prevalent in the war-torn nations of the Middle East.

Background Valuation of the economic cost of antimicrobial resistance (AMR) is important for decision making and should be estimated accurately. Highly variable or erroneous estimates may alarm policy...

To the Editor: The AVENIR (Azithromycine pour la Vie des Enfants au Niger: Implementation et Recherche) trial reported by O’Brien et al. (Aug. 22/29 issue)1 shows the mortality benefit of mass dist...

Introduction Empirical antibiotic therapy is essential for treating bloodstream infections (BSI), yet there is limited evidence from resource-limited settings. We quantified the association of inappro...